• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Amicus Therapeutics Inc.

    11/12/25 6:08:03 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    AMICUS THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    03152W109

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03152W109


    1Names of Reporting Persons

    WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    14,343,352.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    15,974,254.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,974,254.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AMICUS THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    47 HULFISH STREET, PRINCETON, NEW JERSEY, 08542
    Item 2. 
    (a)Name of person filing:

    William Blair Investment Management, LLC
    (b)Address or principal business office or, if none, residence:

    150 North Riverside Plaza, Chicago, IL 60606
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    03152W109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    15,974,254
    (b)Percent of class:

    5.2%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    14,343,352

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    15,974,254

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
     
    Signature:Walter R. Randall, Jr.
    Name/Title:Chief Compliance Officer
    Date:11/12/2025
    Get the next $FOLD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/29/2025$14.50Outperform → Market Perform
    Leerink Partners
    12/22/2025$14.50Buy → Hold
    TD Cowen
    12/17/2025$17.00Buy
    Citigroup
    9/18/2025$14.00Hold → Buy
    Needham
    7/17/2025$108.00Equal-Weight → Overweight
    Morgan Stanley
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    More analyst ratings

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amicus Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Amicus Therapeutics from Outperform to Market Perform and set a new price target of $14.50

    12/29/25 7:10:03 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics downgraded by TD Cowen with a new price target

    TD Cowen downgraded Amicus Therapeutics from Buy to Hold and set a new price target of $14.50

    12/22/25 8:32:24 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Amicus Therapeutics with a new price target

    Citigroup initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $17.00

    12/17/25 9:12:12 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    SEC Filings

    View All

    SEC Form DEFA14A filed by Amicus Therapeutics Inc.

    DEFA14A - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    12/19/25 9:26:26 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

    8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    12/19/25 9:24:53 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

    SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    12/3/25 11:13:29 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

    BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027 Conference Call Today at 8:15 a.m. Eastern Tim

    12/19/25 7:45:00 AM ET
    $BMRN
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

    AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ:SNGX) (Profile), a late-stage biopharmaceutical develope

    12/4/25 8:30:00 AM ET
    $AMGN
    $CTOR
    $FOLD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Rosenberg Ellen covered exercise/tax liability with 43,109 shares, decreasing direct ownership by 8% to 464,601 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    1/6/26 7:47:49 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Castelli Jeff covered exercise/tax liability with 30,007 shares, decreasing direct ownership by 7% to 409,311 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    1/6/26 7:47:09 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Prout Samantha covered exercise/tax liability with 15,683 shares, decreasing direct ownership by 11% to 125,951 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    1/6/26 7:46:28 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Financials

    Live finance-specific insights

    View All

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

    BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027 Conference Call Today at 8:15 a.m. Eastern Tim

    12/19/25 7:45:00 AM ET
    $BMRN
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

    Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended September 30, 2025. "Amicus achieved yet another impressive quarter, delivering revenue growth of 17 percent and reaching the milestone of GAAP profitability. We served more patients than ever before, driven by new Galafold starts and gr

    11/4/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Leadership Updates

    Live Leadership Updates

    View All

    Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

    Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

    8/21/23 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

    PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

    6/14/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

    Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

    5/6/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:00:58 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amicus Therapeutics Inc.

    SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 11:37:23 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:31:54 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care